Your browser doesn't support javascript.
loading
Sample size requirements for detecting treatment effect heterogeneity in cluster randomized trials.
Yang, Siyun; Li, Fan; Starks, Monique A; Hernandez, Adrian F; Mentz, Robert J; Choudhury, Kingshuk R.
Affiliation
  • Yang S; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.
  • Li F; Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA.
  • Starks MA; Center for Methods in Implementation and Prevention Science, Yale School of Public Health, New Haven, Connecticut, USA.
  • Hernandez AF; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
  • Mentz RJ; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
  • Choudhury KR; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Stat Med ; 39(28): 4218-4237, 2020 12 10.
Article in En | MEDLINE | ID: mdl-32823372
Cluster randomized trials (CRTs) refer to experiments with randomization carried out at the cluster or the group level. While numerous statistical methods have been developed for the design and analysis of CRTs, most of the existing methods focused on testing the overall treatment effect across the population characteristics, with few discussions on the differential treatment effect among subpopulations. In addition, the sample size and power requirements for detecting differential treatment effect in CRTs remain unclear, but are helpful for studies planned with such an objective. In this article, we develop a new sample size formula for detecting treatment effect heterogeneity in two-level CRTs for continuous outcomes, continuous or binary covariates measured at cluster or individual level. We also investigate the roles of two intraclass correlation coefficients (ICCs): the adjusted ICC for the outcome of interest and the marginal ICC for the covariate of interest. We further derive a closed-form design effect formula to facilitate the application of the proposed method, and provide extensions to accommodate multiple covariates. Extensive simulations are carried out to validate the proposed formula in finite samples. We find that the empirical power agrees well with the prediction across a range of parameter constellations, when data are analyzed by a linear mixed effects model with a treatment-by-covariate interaction. Finally, we use data from the HF-ACTION study to illustrate the proposed sample size procedure for detecting heterogeneous treatment effects.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Research Design Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Stat Med Year: 2020 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: Research Design Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Stat Med Year: 2020 Type: Article Affiliation country: United States